Patents by Inventor Ruibin Lin

Ruibin Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • REAL-TIME GROUND FUSION METHOD AND SYSTEM BASED ON BINOCULAR STEREO VISION, AND INTELLIGENT TERMINAL
    Publication number: 20230147557
    Abstract: A real-time ground fusion system is based on binocular stereo vision and an intelligent terminal. The method for accomplish real-time ground fusion includes: S1 of obtaining a disparity map about a same road scenario, and converting a disparity map in a target region into a 3D point cloud; S2 of performing pose conversion on a current frame and a next frame adjacent to the current frame, and performing inverse conversion on a 3D point cloud of the current frame; and S3 of repeating S2 with each frame in the target region as the current frame, so as to achieve ground fusion. Through the conversion and fusion of adjacent frames, holes caused by the projection of the disparity map can be filled to assist driving and output accurate height data, thereby improving comfortableness.
    Type: Application
    Filed: April 12, 2022
    Publication date: May 11, 2023
    Inventors: Ruibin LIN, Hua CHAI, Zhipeng XIAO, Jun LIAO, Bin CHEN, Jian LI, Ran MENG, Ya LIU, Huosheng XU
  • ?-lactamase inhibitors
    Patent number: 10738051
    Abstract: Disclosed in the present invention is a type of novel ?-lactamase inhibitors, and specifically disclosed are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: August 11, 2020
    Assignee: QILU PHARMACEUTICAL CO., LTD.
    Inventors: Boyu Hu, Charles Z. Ding, Zhigang Huang, Ruibin Lin, Minliang Xiao, Jinsheng Xie, Shuhui Chen, Cheng Li
  • NOVEL BETA-LACTAMASE INHIBITORS
    Publication number: 20200010467
    Abstract: Disclosed in the present invention is a type of novel ?-lactamase inhibitors, and specifically disclosed are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 2, 2017
    Publication date: January 9, 2020
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Boyu HU, Charles Z. DING, Zhigang HUANG, Ruibin LIN, Minliang XIAO, Jinsheng XIE, Shuhui CHEN, Cheng LI
  • Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
    Patent number: 9969719
    Abstract: Disclosed is a substituted 2H-pyrazole derivative serving as a selective CDK4/6 inhibitor. Specifically, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt thereof which serves as a selective CDK4/6 inhibitor.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: May 15, 2018
    Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., MEDSHINE DISCOVERY INC.
    Inventors: Charles Z. Ding, Shuhui Chen, Baoping Zhao, Zhaobing Xu, Yingchun Liu, Ruibin Lin, Fei Wang, Jian Li
  • SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE SERVING AS ANTICANCER DRUG
    Publication number: 20180072707
    Abstract: Disclosed is a substituted 2H-pyrazole derivative serving as a selective CDK4/6 inhibitor. Specifically, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt thereof which serves as a selective CDK4/6 inhibitor.
    Type: Application
    Filed: March 10, 2016
    Publication date: March 15, 2018
    Inventors: Charles Z. Ding, Shuhui Chen, Baoping Zhao, Zhaobing Xu, Yingchun Liu, Ruibin Lin, Fei Wang, Jian Li